<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728919</url>
  </required_header>
  <id_info>
    <org_study_id>R200090</org_study_id>
    <nct_id>NCT04728919</nct_id>
  </id_info>
  <brief_title>Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection</brief_title>
  <official_title>Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study of the relation of COVID-19 infection and its severity to upper and lower airway&#xD;
      nitric oxide, upper airway viral load and lung function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Materials and methods: Prospective cohort of 40 COVID-19, severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2), positive patients from Tampere university hospital region are&#xD;
      recruited to the study. Forty COVID-19 negative patients with similar symptoms act as a&#xD;
      control group.&#xD;
&#xD;
      All subjects are screened for other respiratory viruses with RT-PCR-multiplex tests. Viral&#xD;
      loads of SARS-CoV-2 from anterior nasal cavity, nasopharynx, throat and saliva are evaluated&#xD;
      by RT-PCR (Ct value) and antigen testing (RLU value).&#xD;
&#xD;
      During the first visit NEWS (National Early Warning Score), recorded pulmonary auscultation&#xD;
      (Thinklabs One, Thinklabs Medical LLC), impulse oscillometry (Tremoflo, THORASYS Thoracic&#xD;
      Medical Systems Inc), FeNO (fractional exhaled nitric oxide) and FnNO (fractional nasal&#xD;
      nitric oxide) (NIOX VERO®,Circassia) are conducted. All aforementioned and a spirometry are&#xD;
      measured again after 2 months.&#xD;
&#xD;
      Aims: To evaluate the relation of COVID-19 infection and its severity to upper and lower&#xD;
      airway nitric oxide, viral load and lung function. To compare the capability of RT-PCR in&#xD;
      detecting SARS-CoV-2 RNA from saliva, anterior nasal swab samples and oropharyngeal swap&#xD;
      samples vs. the golden standard of nasopharyngeal swab samples. To compare the results of&#xD;
      RT-PCR and antigen test in detecting SARS-CoV-2 from nasal and pharyngeal sample sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load of SARS-CoV-2 from different sample sites</measure>
    <time_frame>0 months</time_frame>
    <description>RT-PCR (Ct value) and antigen testing (RLU value)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper respiratory tract viruses</measure>
    <time_frame>0 months</time_frame>
    <description>RT-PCR-multiplex tests, from nasopharyngeal sample site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FeNO</measure>
    <time_frame>Baseline</time_frame>
    <description>Fractional exhaled nitric oxide in ppb obtained NIOX VERO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FnNO</measure>
    <time_frame>Baseline</time_frame>
    <description>Nasal nitric oxide in ppb obtained NIOX VERO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FeNO</measure>
    <time_frame>2 months</time_frame>
    <description>Fractional exhaled nitric oxide in ppb obtained NIOX VERO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FeNO</measure>
    <time_frame>BAseline and at 2 months</time_frame>
    <description>FeNO at 2 months - FeNO at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FnNO</measure>
    <time_frame>2 months</time_frame>
    <description>Nasal nitric oxide in ppb obtained NIOX VERO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHange in FnNO</measure>
    <time_frame>Baseline and at 2 months</time_frame>
    <description>FnNO at 2 moths - FnNO at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway resistance at 20Hz, R20</measure>
    <time_frame>Baseline</time_frame>
    <description>Airway resistance at 20Hz obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway resistance at 5Hz, R5</measure>
    <time_frame>Baseline</time_frame>
    <description>Airway resistance at 5Hz obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway resistance at 20 Hz, R20</measure>
    <time_frame>2 months</time_frame>
    <description>Airway resistance at 20 Hz obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in R20</measure>
    <time_frame>Baseline and at 2 months</time_frame>
    <description>R20 at 2 months - R20 at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway resistance at 5Hz, R5</measure>
    <time_frame>2 months</time_frame>
    <description>Airway resistance at 5Hz obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in R5</measure>
    <time_frame>Baseline and at 2 months</time_frame>
    <description>R5 at 2 months - R5 at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactance at 5Hz (X5)</measure>
    <time_frame>Baseline</time_frame>
    <description>Airway reactance at 5 Hz obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactance at 5Hz (X5)</measure>
    <time_frame>2 months</time_frame>
    <description>Airway reactance at 5 Hz obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in X5</measure>
    <time_frame>Baseline and at 2 months</time_frame>
    <description>X5 at 2 months - X5 at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resonant frequency (Fres)</measure>
    <time_frame>Baseline</time_frame>
    <description>Resonant frequency (Fres) obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resonant frequency (Fres)</measure>
    <time_frame>2 months</time_frame>
    <description>Resonant frequency (Fres) obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fres</measure>
    <time_frame>Baseline and at 2 months</time_frame>
    <description>Fres at 2 months - Fres at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactance area (AХ)</measure>
    <time_frame>Baseline</time_frame>
    <description>Reactance area (AХ) obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactance area (AХ)</measure>
    <time_frame>2 months</time_frame>
    <description>Reactance area (AХ) obtained from Impulse oscillometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in AX</measure>
    <time_frame>Baseline and at 2 months</time_frame>
    <description>AX at 2 months - AX at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>2 months</time_frame>
    <description>Forced expiratory volume in 1 second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>2 months</time_frame>
    <description>Forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VC</measure>
    <time_frame>2 months</time_frame>
    <description>Vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>2 months</time_frame>
    <description>Forced expiratory volume in 1 second divided by forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/VC</measure>
    <time_frame>2 months</time_frame>
    <description>Forced expiratory volume in 1 second divided by vital capacity</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>COVID-19 positive cases</arm_group_label>
    <description>Subjects with acute respiratory infection and positive COVID-19 test, who are well enough to be treated at home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 negative controls</arm_group_label>
    <description>Subjects with acute respiratory infection and negative COVID-19 test, who are well enough to be treated at home.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptoms of COVID-19 infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  capable of breathing through nose, no need of supplemental oxygen, symptom onset&#xD;
             within 10 days, positive SARS-CoV-2 test in Fimlab and capable of performing all&#xD;
             required tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  need of supplemental oxygen, pregnancy, lactation, incapability of performing the&#xD;
             tests for any reason, use of organic nitrate medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Lehtimäki, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pekka Tamminen, M.D.</last_name>
    <phone>+3583311611</phone>
    <email>pekka.tamminen@tuni.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pekka Tamminen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Lauri Lehtimäki</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

